Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis

Enrolling by invitation

Conditions studied: Hepatocellular Carcinoma, Cirrhosis

In brief

The research team will evaluate the effectiveness of an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.

Key facts

Study ID

NCT06624189

Run by

NYU Langone Health

People needed

1300

Starts

2024-11-20

Expected to finish

2026-07-24

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• cirrhosis diagnosis,
• 6 months or more after since most recent imaging.

You may not qualify if…

• previous liver transplant,
• HCC diagnosis,
• receiving hospice care,
• completed external imaging in the past 6 months.

Where it is running

• NYU Langone Health — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.